| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 抗肿瘤药物(元) | - | 132,942,624.59 | - | 208,665,152.62 |
| 自身免疫药物(元) | - | 601,790,657.10 | - | 489,942,467.66 |
| 代加工业务(元) | 3,982,300.89 | - | 2,400,442.48 | - |
| 技术服务(元) | 2,886,204.82 | - | 1,351,231.59 | - |
| 技术授权许可(元) | 28,945,403.24 | - | 42,071,399.05 | - |
| 药品销售(元) | 406,073,932.45 | - | 356,280,221.83 | - |
| 其他(元) | - | 8,432,778.40 | 183,426.91 | 6,187,032.56 |
| 营业成本(元) | ||||
| 抗肿瘤药物(元) | - | 98,259,229.41 | - | 129,819,709.97 |
| 自身免疫药物(元) | - | 128,617,297.91 | - | 57,488,163.04 |
| 代加工业务(元) | 1,562,018.14 | - | 883,629.03 | - |
| 技术服务(元) | 468,687.74 | - | - | - |
| 技术授权许可(元) | - | - | - | - |
| 药品销售(元) | 96,256,566.17 | - | 132,571,096.48 | - |
| 其他(元) | - | 2,665,368.75 | 54,594.34 | 5,991,089.76 |
| 毛利(元) | ||||
| 抗肿瘤药物(元) | - | 34,683,395.18 | - | 78,845,442.65 |
| 自身免疫药物(元) | - | 473,173,359.19 | - | 432,454,304.62 |
| 代加工业务(元) | 2,420,282.75 | - | 1,516,813.45 | - |
| 技术服务(元) | 2,417,517.08 | - | - | - |
| 技术授权许可(元) | 28,945,403.24 | - | - | - |
| 药品销售(元) | 309,817,366.28 | - | 223,709,125.35 | - |
| 其他(元) | - | 5,767,409.65 | 128,832.57 | 195,942.80 |
| 毛利率(%) | ||||
| 抗肿瘤药物(%) | - | 26.09 | - | 37.79 |
| 自身免疫药物(%) | - | 78.63 | - | 88.27 |
| 代加工业务(%) | 60.78 | - | 63.19 | - |
| 技术服务(%) | 83.76 | - | - | - |
| 技术授权许可(%) | - | - | - | - |
| 药品销售(%) | 76.30 | - | 62.79 | - |
| 其他(%) | - | 68.39 | 70.24 | 3.17 |
| 收入构成(%) | ||||
| 抗肿瘤药物(%) | - | 17.89 | - | 29.61 |
| 自身免疫药物(%) | - | 80.98 | - | 69.52 |
| 代加工业务(%) | 0.90 | - | 0.60 | - |
| 技术服务(%) | 0.65 | - | 0.34 | - |
| 技术授权许可(%) | 6.55 | - | 10.46 | - |
| 药品销售(%) | 91.90 | - | 88.56 | - |
| 其他(%) | - | 1.13 | 0.05 | 0.88 |
| 毛利构成(%) | ||||
| 抗肿瘤药物(%) | - | 6.75 | - | 15.41 |
| 自身免疫药物(%) | - | 92.12 | - | 84.55 |
| 代加工业务(%) | 0.70 | - | 0.67 | - |
| 技术服务(%) | 0.70 | - | 0.00 | - |
| 技术授权许可(%) | 8.42 | - | 0.00 | - |
| 药品销售(%) | 90.17 | - | 99.27 | - |
| 其他(%) | - | 1.12 | 0.06 | 0.04 |